Search Results

Most drugs don’t fail at the receptor level—they fail before they even reach it. In every lab, candidates fail not because they lack potency at a receptor, but because they stumble at Even the most elegant GPCR ligand can fail if it never reaches its receptor. potency under high substrate conditions, such as ATP-rich cancer cells, where orthosteric inhibitors fail

But behind every “new” assay is a decade of design, failure, and rethinking.

Every GPCR assay that makes it to market carries years of failures, late-night ideas, risky bets, and Built to Fail, Built to Win: The IP One Gamble After the success of their cAMP assay, Trinquet’s team Classic pH probes failed in plate readers—too noisy, too dim. pHSense rewrote that rule, enabling high-throughput You’ll fail 90% of the time.

But some leak current, like a switch glowing faintly in the dark. Model patient-like pathophysiological states (e.g., reduced receptor expression in heart failure).

But here’s the truth: too many programs still fail because early decisions were built on shaky mechanistic Months of wasted resources, failed translation, and opportunity loss.

Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail Avoid compensatory misreads:  Renin inhibition drops BP in normals, but not in heart failure—because

inhibitor that lowers blood pressure in healthy volunteers might not drop blood pressure at all in heart failure bradycardia that blunts its heart rate liability—making it a better inotrope than isoproterenol in heart failure Your molecule isn’t failing—your model might be too simple.

Avoid expensive mirages:  Spot when “good” equilibrium curves mask time-dependent binding that will fail

A career pivot is not a failure—it’s a refined strategy. Catherine's decision to defer pharmacy school was a leap of faith that opened new doors.

reshape how you evaluate and advance lead compounds, potentially saving your team from costly late-stage failures Are your promising in vitro results failing to translate into real-world clinical success? Dr. Threat Avoided:  Prevent costly late-stage failures by incorporating kinetic modeling early in your pipeline

A strong agonist, fails to reduce binding of a labeled NAM—not because of irreversibility, but because The takeaway:  what looks like pharmacology failure may be a systems problem .

A GPCR program can have world-class science, top-tier talent, and millions in funding — and still fail A few familiar failure points: Fragmented Data: GPCR programs spew data across files, folders, and inboxes

latest lecture delivers a paradigm shift for pharmacologists working on drugs where in vitro potency fails

This opens up a new pharmacological space—and a reason to revisit “failed” targets with fresh eyes. access transforms the kinetic profile of your drug, which may be the difference between success and failure

Inefficient structure-activity relationship (SAR) cycles Wasted optimization efforts Focus on leads that fail

This is a chance to shape the next scientific consensus on how GPCRs work, signal, and fail.

Solve the in vitro/in vivo disconnect:  Understand why traditional potency measurements often fail to Discover how to identify and target cryptic intracellular allosteric sites, opening up new avenues for "failed

Alex Serafini  explains, this conventional bottom-up approach often fails to deliver therapies that truly Why This Approach Matters In pain research, bottom-up approaches often fail to translate.

of RGS proteins — particularly RGS4  — in modulating pain circuits in ways that traditional targets fail

Teams chase the wrong assays, too late to pivot Milestones slip—and nobody realizes until it’s too late Failing science stalls without operational structure ✅ Scattered data = missed insights = wasted time ✅ You can’t fail

In a field like GPCR research (where data complexity and failure rates are high), scientific rigor thrives

You'll learn why some agonists succeed in sensitive tissues but fail elsewhere—and how this knowledge

And yes, you'll even meet the man who turned failed experiments into a Nobel Prize-winning discovery

Here’s the surprising truth: up to 80% of GPCR-targeted drugs fail—not because of poor chemistry, but

Moment: Try the Crazy Idea When a collaborator offered a neuroma model (one where opioids usually fail

“We’ve seen these modulators rescue opioid function where it completely fails in neuroma models.

Collaboration Targeting Neurological Diseases Achieves First R&D Milestone Tectonic bets on GPCR heart failure

Monlunabant by Inversago Pharma for Metabolic Syndrome: Likelihood of Approval Tectonic bets on GPCR heart failure

on their work entitled β-arrestins and their potential role in heart failure. Dr. inflammatory diseases β-adrenergic receptor signaling mediated by β-arrestins and its potential role in heart failure

Different reviews have extensively described the success and failure in drug discovery on chemokine receptors